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IntroductIon
“The scientist and science provide the means, the politician 
and politics decide the ends.”
‑Alvin M. Weinberg[1]
Regulatory science is an established discipline that entails 
the application of the scientific method to support regulatory 
and other policy objectives.[2] Simply put, when medical 
Abstract
Unlocking the full potential of pathology data by gaining computational access to histological pixel data and metadata (digital pathology) 
is one of the key promises of computational pathology. Despite scientific progress and several regulatory approvals for primary diagnosis 
using whole‑slide imaging, true clinical adoption at scale is slower than anticipated. In the U.S., advances in digital pathology are often 
siloed pursuits by individual stakeholders, and to our knowledge, there has not been a systematic approach to advance the field through a 
regulatory science initiative. The Alliance for Digital Pathology (the Alliance) is a recently established, volunteer, collaborative, regulatory 
science initiative to standardize digital pathology processes to speed up innovation to patients. The purpose is: (1) to account for the patient 
perspective by including patient advocacy; (2) to investigate and develop methods and tools for the evaluation of effectiveness, safety, and 
quality to specify risks and benefits in the precompetitive phase; (3) to help strategize the sequence of clinically meaningful deliverables; (4) 
to encourage and streamline the development of ground‑truth data sets for machine learning model development and validation; and (5) to 
clarify regulatory pathways by investigating relevant regulatory science questions. The Alliance accepts participation from all stakeholders, 
and we solicit clinically relevant proposals that will benefit the field at large. The initiative will dissolve once a clinical, interoperable, 
modularized, integrated solution (from tissue acquisition to diagnostic algorithm) has been implemented. In times of rapidly evolving 
discoveries, scientific input from subject‑matter experts is one essential element to inform regulatory guidance and decision‑making. The 
Alliance aims to establish and promote synergistic regulatory science efforts that will leverage diverse inputs to move digital pathology 
forward and ultimately improve patient care.
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research provides a novel solution to a health need, regulatory 
science applies the scientific method to assess benefits and 
risks before marketing for clinical use. To assess benefits and 
risks, regulatory scientists develop new tools, standards, and 
approaches to evaluate the effectiveness, safety, and quality 
of medical products. A primary challenge in the field of digital 
pathology is the lack of understanding that strong relationships 
between regulatory, basic, and translational scientists can 
substantially improve clinical innovation.[3‑6] For example, 
regulatory science is not restricted to regulatory agencies.[2,4‑6] 
As a scientific discipline, regulatory science challenges current 
concepts of benefit and risk assessments, submission and 
approval strategies, patient involvement, and various ethical 
aspects. Regulatory science includes the creation of a scientific 
dialog for launching new ideas – not only derived from industry 
and regulatory authorities but also by, for example, academics, 
clinicians, and patients.[7] It has been recognized that regulatory 
science can have a significant impact in bringing new devices 
to patients in need.[7]
Here, we outline a recently established, volunteer, collaborative 
regulatory science initiative termed the Alliance for Digital 
Pathology (the Alliance). To prevent confusion, our intent is to 
familiarize the community with the aims, scope, and rationale 
of the Alliance. The Alliance aims to move the field of digital 
pathology forward by systematically assessing relevant aspects 
and providing publicly available resources (e.g., data, tools, 
and methods) to inform and improve the relevant regulatory 
guidance landscape.[8] Our premise (thesis) is that the Alliance 
promotes regulatory science as a bridge between digital 
pathology (the means) and moving the field of diagnostic 
pathology forward (the ends). By promoting regulatory 
science, the Alliance helps to unlock the potential of new 
technologies and thereby overcomes the dichotomy illustrated 
in the epigraph by Dr. Weinberg.[1]
toward an operatIonal defInItIon of a clInIcal, 
Interoperable, Integrated SolutIon for dIgItal 
pathology
The key aim of the Alliance is to help convert the 
existing (traditional) pathology technologies and workflows 
into interoperable, digitally enhanced solutions by contributing 
regulatory science deliverables that can be used to inform 
and improve the applicable regulatory guidance landscape. 
Numerous groups have attempted to specify the relevant 
components of digital pathology solutions;[9‑18] however, 
given the modularized nature of diagnostic pathology, 
defining the specific scope of a digital pathology solution 
is highly context dependent. For example, the variability 
of a stain (e.g., hematoxylin and eosin across or within 
laboratories) may influence the performance of a downstream 
mutation prediction algorithm.[19‑21] In this example, one may 
consider drawing an arbitrary boundary before the staining 
step; however, the fixation and processing method (e.g., 
formalin fixed, paraffin embedded) or even the tissue 
acquisition, handling, or image acquisition[22] may influence 
the performance of the predictor as well. Thus, for the 
purpose of the Alliance, we considered three descriptors for 
the solution. First, we aim toward a clinical (as opposed to 
a research‑based) solution. Second, due to the modularized 
nature of the various subprocesses within the main workflows 
in pathology, we aim for interoperability of systems. Third, 
to account for the various and arbitrary boundaries of 
workflow steps (modules) and technologies relevant for a 
given task (intended use), we consider every step, from the 
medical procedure acquiring the cell or tissue sample all the 
way to the fully integrated diagnostic output (e.g., report 
or model output), as relevant. As opposed to an end‑to‑end 
solution, where the supplier of an application or system will 
provide all the hardware and/or software to meet specific 
requirements, we are aiming for modularized solutions 
within the main workflow. We refer to these three solution 
descriptors (clinical, interoperable, and modularized) as an 
“integrated solution” for digital pathology. We acknowledge 
that this definition is operational and arguably incomplete yet 
represents a technique that enables flexible modeling to solve 
challenging problems.[23‑26]
the MultIfaceted nature of dIgItal pathology 
needS IncreaSed regulatory clarIty
Digital pathology has grown into a multimillion‑dollar 
vendor landscape,[27] and the application of machine learning 
algorithms holds big promise for improving diagnostics 
in numerous ways.[28‑30] Despite this active and promising 
research, the Food and Drug Administration (FDA) has 
only recently authorized two digital pathology whole‑slide 
imaging (WSI) systems for primary diagnosis.[3,9,11,31,32] Even 
with the authorization of two WSI systems and numerous 
use cases,[12‑14,18,33‑38] in the U.S., we see few hospitals 
changing their daily clinical operations to integrate WSI for 
primary diagnosis.[39‑43] Clinical laboratories face additional 
challenges when implementing high complexity and/or 
high‑risk medical devices coupled with software solutions 
as laboratory‑developed tests (LDTs).[44‑46] For example, 
even when using an FDA‑authorized whole‑slide imaging 
device, the approval or clearance does not eliminate the need 
for an individual laboratory to verify the performance of 
these systems for the specific intended diagnostic purpose. 
Specifically, Clinical Laboratory Improvement Amendments 
of 1988 or CLIA ’88 in the US requires at least verification[47] 
and substantial adaptation to implement.[48‑52]
One value proposition for digital pathology is to take advantage 
of the digital nature of WSI and use artificial intelligence/
machine learning (AI/ML) algorithms to support clinical 
decisions.[11,53] In fact, several groups have proposed that AI/
ML will unlock the full potential of digital pathology.[53,54]
To examine the current regulatory guidance landscape related 
to digital pathology and AI, four authors (HDM, RH, EA, and 
JKL) performed a review of pertinent documents from the FDA. 
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Figure 1: Overview of selected FDA guidance documents. Four of the authors (HM, RH, EA, and JKL) performed a meta‑review of selected FDA guidance 
documents relevant to the scope and aims of the Alliance. The figure shows grouping of these guidance documents across five dimensions over time. 
Please note: the numbers refer to the order of review during the meta‑review process; Supplemental Table 1 provides the original release dates, the 
official FDA guidance title, and the issuer. AI/ML: Artificial intelligence/machine learning; CMS: Centers for Medicare and Medicaid Services; FDA: Food 
and Drug Administration; IMDRF: International Medical Device Regulators Forum; MDDT: Medical Device Development Tools; SaMD: Software as a 
Medical Device; QMS: Quality management system; WSI: Whole‑slide imaging
J Pathol Inform 2020, 1:22 http://www.jpathinformatics.org/content/11/1/22
Journal of Pathology Informatics 3
We noted the official release dates and assigned each document 
to one of five dimensions [Figure 1 and Supplemental Table 1]. 
By plotting these documents and dimensions over time, 
we show how the regulatory guidance landscape evolves. 
A novice in the field may look for one comprehensive guidance 
document for digital pathology and may be discouraged by the 
initial complexity; however, we hope that Figure 1 provides 
a reasonable starting point for learning the current regulatory 
guidance landscape. As we show [Figure 1, arrows], the 
regulatory guidance landscape adapts over time as technologies 
and the associated regulatory science matures. One key element 
in the multistep process to improve the regulatory guidance 
landscape is critical scientific input from subject‑matter 
experts.[3‑5,10,11,15,53] We strongly believe that “watching and 
waiting” will not help the case of digital pathology. Similarly, 
workarounds[84‑89] turn into long and winding roads that 
ultimately end at the FDA and within the FDA’s regulatory 
framework.[83] The Alliance intends to organize subject‑matter 
experts and provide scientific input.
Simply put, the practical dilemma in digital pathology is 
that developers are challenged to create an FDA submission 
following the evolving and complex regulatory guidance 
landscape, and the adoption of WSI by pathologists is slowed 
because they cannot realize the full potential and utility of 
digital pathology and AI/ML without full clinical integration. 
The field of digital pathology is looking for broader guidance, 
practical advice, and streamlined regulatory pathways to help 
navigate this uncharted and exciting territory.
regulatory ScIence, the precoMpetItIve Space, 
and real‑world evIdence
FDA clearance of a medical device offers a vendor market 
access. Once introduced, market forces tend not to encourage the 
vendor to make the device or its subsystems interoperable.[55‑61] 
We like to emphasize that routine diagnostic pathology is highly 
modularized and the practice does not lend itself easily to 
nonmodular, locked down solutions.[3,9‑11,27,50,51,54,62] The Alliance 
believes that it can promote interoperability and innovation by 
launching initiatives and creating deliverables (data, standards, 
tools, and methods) in the precompetitive space. Organizing 
industry to work collaboratively in the precompetitive space 
will eliminate unnecessary or duplicative (proprietary) efforts 
and thereby save all parties’ time, money, and resources when 
pursuing device authorizations.[63] The Alliance initiatives and 
deliverables will speed clinical integration and carry mutual 
benefit to all stakeholders, including regulators, clinicians, 
manufacturers, and most importantly, patients.
Real‑world evidence (RWE) comes from the competitive, 
postmarket space. RWE can identify trends in adverse 
events, summarize where resources are being spent, and 
track the impact of a new diagnostic device or therapy in 
terms of patient outcomes. RWE can support clinical practice 
guidelines and decisions about reimbursement and policy. 
Furthermore, RWE can inform regulatory decision making, 
as effectively demonstrated by the Medical Device Innovation 
Consortium,[64,65] the National Evaluation System for health 
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Figure 2: Concept, process, role, and proposed benefits of the Alliance. (a) The approach of the Alliance is to deliver tools via precompetitive FDA 
programs and use the gained experience to support effective FDA review. The concept also includes a predetermined exit strategy (i.e., one fully 
integrated solution for digital pathology). (b) The process of moving Alliance projects forward is essentially a two‑step, multidisciplinary peer review by 
subject‑matter experts. First, projects are reviewed, and after a multidisciplinary selection process that emphasizes the patient perspective and relevance 
for patient care, the steering committee (jointly with relevant partners) attempts to allocate resources. (c) Role and proposed benefits of the Alliance 
exemplified using the high‑throughput truthing project for tumor‑infiltrating lymphocytes as a biomarker in breast cancer. AMCs: Academic medical 
centers; MDDT: Medical Device Development Tools (precompetitive FDA submission program);  Mock: mock submission program (precompetitive 
FDA submission program); OIR: Office of In vitro Diagnostics and Radiological Health; OPEQ: Office of Product Evaluation and Quality; OSEL: Office 
of Science and Engineering Laboratories; FDA: Food and Drug Administration
ba
c
Technology Coordinating Center,[66] the Patient‑Centered 
Outcomes Research Institute,[67,68] Friends of Cancer 
Research,[69,70] and others.[3,5,6,9,71‑74]
froM Key MISSIon eleMentS to a delIvery 
proceSS
Accomplishing mutual benefit to multiple stakeholders is a 
daunting value proposition that requires a unique regulatory 
science approach and stakeholder involvement for selection 
and prioritization of deliverables. The approach of the 
Alliance [Figure 2a] is to deliver tools by harnessing existing, 
precompetitive FDA programs and use the gained experience 
to inform effective regulation. The approach thereby aims 
to streamline precompetitive and eventually competitive 
submissions that enable faster time to market to improve 
patient care. Regulatory science deliverables, including tools 
and the experience from precompetitive submissions, will be 
shared, and when one integrated solution has been enabled, the 
Alliance can dissolve [Figure 2a]. The key mission elements 
of the Alliance are summarized in Table 1.[75]
To align stakeholder interests, initiatives and deliverables 
need to be prioritized and prioritization requires a process. 
We conceptualized an approach that is composed of 
synergistic review, project components, and resource 
allocation [Figure 2b]. The process starts with synergizing 
various stakeholder interests into concise individual 
projects. An Alliance project may consist of a clinically 
relevant intended use case, a data set (e.g., pixel and 
metadata), and an applicable regulatory science pathway [e.g., 
Figure 2b, triangle]. The Alliance membership, composed of 
subject‑matter experts from various domains, will have the 
opportunity to review, contribute, and potentially modify 
these projects through free and voluntary feedback to the 
project owner. Over time, individual effort and maturation of 
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ideas will result in optimized projects (“big ideas”). To help 
realize the proposed deliverables and/or allocate additional 
resources, we established the Alliance Steering Committee, 
a flexible organizational structure, and a code of conduct 
[Supplemental Table 2].
An example project is illustrated in Figure 2c. A subset 
of members in the Alliance are studying the relevance of 
tumor‑infiltrating lymphocytes (TILs) as a prognostic and 
predictive biomarker.[76,77] The interest in this clinical use 
case led to a collaborative project that includes members 
from the FDA, academic medical centers (AMCs), and 
industry. The project, referred to as the high‑throughput 
truthing (HTT) project, aims to demonstrate the collection and 
use of pathologist annotations for the purpose of evaluating 
AI/ML algorithms and other digital pathology initiatives. 
The project also aims to qualify the glass slides, whole‑slide 
images, and pathologist annotations for evaluating AI/ML 
algorithms through the precompetitive FDA’s Medical Device 
Development Tools (MDDT) program.[78] If qualified, the 
“ground‑truth” materials can serve as a publicly available, 
standardized evaluation “tool” for algorithm evaluation that 
can be used in submissions to the FDA.
In relation to the Alliance, the HTT project was submitted to 
the Alliance and discussed in November 2019. The Alliance 
can contribute in multiple ways to accelerate the realization of 
this and similar projects. First, the Alliance confirmed that the 
aims of the project could benefit many stakeholders.
The discussions provided useful feedback from subject‑matter 
experts regarding the clinical use case, sourcing slides from 
multiple sites, agreements for sharing materials within the 
project, and issues related to sharing materials publicly. 
The discussions also identified future work that could build 
on the lessons, methods, infrastructure, and relationships 
created while pursuing the current aims. Important future 
work identified in the discussions included scaling the effort 
to address generalizability across sites and generalizability 
across use cases.
The Alliance has since provided help with the project [Figure 2b, 
triangle 01, relevant intended use case; Figure 2c, 01] by 
disseminating the project needs. This networking through the 
Alliance has yielded volunteers for sourcing and scanning 
slides, pathologists to annotate slides and images, and 
opportunities to collect data. Connections have been created 
that are expected to help in the development of the statistical 
analyses and the future hosting of slides, images, and 
annotations. Currently, the project is developing the strategy 
and materials for the FDA’s MDDT program [Figure 2b, 
triangle, MDDT; Figure 2c, 03]. The development is a learning 
Table 1: Key mission elements of the Alliance
Definition Explanation
Aim To move the field of digital pathology, AI/ML and 
computational pathology, forward
Focus Key emphasis on regulatory science (“how to get 
to the next step”); inform regulatory guidance 
and decision‑making; explore new regulatory 
programs
Deliverables The Alliance focuses on concrete practical 
deliverables, such as projects or practical 
guidelines, that can be used to inform and 
improve the regulatory guidance landscape 
(regulatory science)
Collaboration We seek participation from all stakeholders
Participatory We aim to sustain and expand the existing 
collaborative infrastructure of the Alliance
Market strategy Focus on the precompetitive space with an 
emphasis on clinical deliverables towards 
financial sustainability for all stakeholders
Patient perspective Make the patient perspective and clinical 
relevance an integral part of the deliverables
Temporary Exit strategy: Once an end‑to‑end solution has 
been clinically integrated, the Alliance ends
Free No membership fees
AI: Artificial intelligence; ML: Machine learning
Figure 3: Workflow steps and Alliance survey results. (a) Digital pathology 
workflows include preanalytical, retrieval, scan (image acquisition), 
clinical data, metadata, machine learning algorithm development, clinical 
integration, clinical utility, and financial sustainability considerations; all 
dependent on the specific use case/application. These workflow steps 
correspond to the axis labels in Figure 3b. (b) The Alliance conducted 
a survey among the members in September 2019. Bar graphs show 
the workflow steps that survey respondents felt the Alliance should 
focus on. These steps are reflected in a workflow diagram in Figure 3a. 
(c) Survey results from September 2019. DICOM: Digital Imaging and 
Communications in Medicine (here referring to an interoperable file format 
for digital pathology); EHR: Electronic health record; H&E: Hematoxylin and 
eosin stain; IHC: Immunohistochemistry; LIMS: Laboratory information 
management system; MDIC: Medical Device Innovation Consortium
b
a
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Figure 4: Roadmap and working groups. (a) Roadmap of in‑person 
events (status May 2020). In addition to the date, the roadmap shows 
hosting organization, key developments, and location of the meetings. 
The graph shows the membership number over time along with the 
number and frequency of the steering committee meetings as well as 
the high‑throughput truthing working group. (b) The Alliance proposed to 
tackle regulatory science deliverables in digital pathology by splitting up 
the topic into eight distinct working groups. Each workgroup is provided 
with the steering committee member (s) and at least one key regulatory 
science deliverable. The steering committee is also responsible for 
minimizing redundancy between the workgroups. AI: Artificial intelligence; 
DPA: Digital Pathology Association; FDA: Food and Drug Administration; 
HTT: High‑throughput truthing (an independent workgroup); MDIC: 
Medical Device Innovation Consortium; ML: Machine learning; USCAP: 
USCAP stands for United States and Canadian Academy of Pathology
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experience for all involved, with contributions from project 
and Alliance subject‑matter and regulatory affairs experts. 
The learning experience is expected to continue through 
official interactions with the FDA related to the MDDT 
submission. Thus, aside from helping to create the ground‑truth 
data set, the Alliance aims to understand regulatory issues 
and processes for future streamlining of other projects and 
submissions. As demonstrated here, a qualified data set may 
result in time‑savings when preparing submissions, generating 
additional tools, and streamlining regulatory review, resulting 
in faster time to market and improved patient care.
who IS the AlliAnce?
The Alliance is composed of a diverse and interdisciplinary group 
of stakeholders who contribute to various aspects of diagnostic 
pathology, from tissue acquisition to reporting and data analytics. 
When deconstructing the clinical digital pathology and AI/ML 
pipeline into its component parts, numerous workflow steps 
have to function in unison [Figure 3a]. Aside from the modular 
nature and operational complexity, these components emphasize 
the  importance of involving various stakeholders with each 
module. Given the novelty of pursuing a collaborative regulatory 
science effort to solve the challenge of clinical adoption of 
digital pathology, we noted a lack of concrete data on interested 
stakeholders and their priorities. In September 2019, we conducted 
an internal survey [n = 42; Supplemental Table 3]. At that 
time, the survey respondents stated that the top 3 deliverables/
workflow steps to focus on should be the DICOM standard, AI/
ML test validation, and pixel and metadata capture [Figure 3b]. 
By self‑reported primary affiliation, the Alliance encompasses 
representation from academia (32%), industry (50%), government 
regulators and nongovernment organizations (12%), and patient 
advocacy groups (6%) [Figure 3c].
MeetIngS, growth, and worKIng groupS
Since its inception in May 2019, the Alliance hosted numerous 
teleconferences, web meetings, and three, in‑person, 
national meetings [Figure 4a]. Over this period (May 
2019–January 2020), the Alliance membership grew from 
an initial n = 37 (July 2019) to n = 322 individuals [May 
2020; Figure 4a]. Each of these in‑person meetings solicited 
collaborative input from stakeholders toward execution of 
concrete regulatory science deliverables. Figure 4a also 
includes the number of participants and frequency of steering 
committee web meetings. By July 2019, it became clear that 
various stakeholders worked on or had interest in distinct topics 
that the Alliance subsequently organized into 8 working groups 
by autumn 2019 [Figure 4b]. These group topics are intended 
to align stakeholders with subject‑matter expertise and interest. 
Clearly, some functional requirements are relevant for multiple 
groups. However, we hope to minimize such redundancies by 
providing clear documentation of projects through appropriate 
project management and frequent content updates. The names 
of the founding and current working group leaders are provided 
in Figure 4b. One example of a regulatory science deliverable 
is also provided per group [Figure 4b]. For further updates or 
details on the various topics, please visit the Alliance website[8] 
or to become a member and get involved.
the AlliAnce facIlItateS regulatory SubMISSIonS
As a first key regulatory science deliverable, in late 2019, 
members of the Alliance submitted an MDDT proposal to 
the FDA for review (HTT project described above). The 
experience gained through this submission will create a starting 
point and testing ground for the proposed approach of the 
Alliance. In contrast to the largely confidential submission 
owned by the submitting entity (typically represented through 
a consulting firm and/or a regulatory affairs division), 
gaining and sharing the submission experience may inform 
subsequent submissions, and Alliance members can draw 
from the experience of these submissions. This particular 
concept is new to digital pathology. Similarly, we consider 
several precompetitive submission programs by the FDA[78,79] 
a paradigm shift that enables different ways to engage with 
regulatory entities. Importantly, the Alliance intends to create 
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a repository of submission documents as a resource to bolster 
subsequent submissions with the collective experience 
of previous submitters. We propose that the field, and in 
particular patients,[80] will ultimately benefit from sharing 
the experiences of Alliance members who have submitted to 
regulatory agencies.
concluSIon
In the current environment of sparse and dispersed regulatory 
guidance for digital pathology and AI/ML, with siloed pursuits 
by diverse stakeholders, the Alliance saw an opportunity to 
establish an important missing element: a precompetitive 
regulatory science collaboration. We believe that for patients 
to benefit from highly complex new technologies, benefit 
and risk assessments are essential.[81,82] The Alliance helps 
tackle this daunting task (i. e., benefit and risk assessment for 
digital pathology and AI/ML) through regulatory sciences 
with the hope of successful clinical integration and improved 
patient care. That said, there are numerous issues that we 
need to address. For example, we want to investigate and 
develop protocols and definitions for continuous performance 
assessments of continuously learning ML algorithms. 
Similarly, approaching financial sustainability will require 
clear demonstration of clinical utility. However, the fact 
that numerous unanswered questions persist represents an 
opportunity for other agencies, regulatory entities, professional 
groups, and collaborative movements (like the Alliance) to step 
up and drive developments toward comprehensive risk and 
safety assessments. It is important to emphasize the crucial 
importance of funding for regulatory and implementation 
science projects, in particular those that aim to inform 
technically appropriate and efficient science‑based regulatory 
decision‑making processes. Such funding is needed to advance 
cutting‑edge innovations into clinical practice. In summary, the 
Alliance aims to advance the field of digital pathology and we 
hope that synergistic efforts between various stakeholders and 
regulatory scientists will ultimately speed the improvement of 
patient care. This begs the question: Who, if not us?
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Supplemental Table 1: Meta-review of pertinent Food and Drug Administration documents
Date n* Title Issuer
January 11, 2002 16 General Principles of Software Validation
https://www.fda.gov/media/73141/download
CDRH and OPEQ




August 17, 2011 1 Advancing Regulatory Science at FDA
https://www.fda.gov/media/81109/download
FDA
July 02, 2012 12 Computer‑Assisted Detection Devices Applied to Radiology Images and Radiology 
Device Data ‑ Premarket Notification [510(k)] Submissions
https://www.fda.gov/media/77635/download
CDRH, OSEL, and 
OPEQ
July 02, 2012 13 Clinical Performance Assessment: Considerations for Computer‑Assisted Detection 
Devices Applied to Radiology Images and Radiology Device Data ‑ Premarket 
Approval (PMA) and Premarket Notification [510(k)] Submissions
https://www.fda.gov/media/77642/download
CDRH, OSEL, and 
OPEQ
December 09, 2013 17 Software as a Medical Device (SaMD): Key Definitions
http://www.imdrf.org/docs/imdrf/final/technical/imdrf‑tech‑131209‑samd‑key‑
definitions‑140901.pdf
IMDRF and SaMD 
WG




IMDRF and SaMD 
WG




October 02, 2015 19 Software as a Medical Device (SaMD): Application of Quality Management System
http://www.imdrf.org/docs/imdrf/final/technical/imdrf‑tech‑151002‑samd‑qms.pdf
IMDRF and SaMD 
WG
April 20, 2016 6 Technical Performance Assessment of Digital Pathology Whole Slide Imaging Devices
https://www.fda.gov/media/90791/download
CDRH, OPEQ, OHT7, 
and DMGP
August 24, 2016 2 Patient Preference Information ‑ Voluntary Submission, Review in Premarket Approval 
Applications, Humanitarian Device Exemption Applications, and De Novo Requests, 
and Inclusion in Decision Summaries and Device Labeling
https://www.fda.gov/media/92593/download
CDRH and OCD




August 10, 2017 4 Qualification of Medical Device Development Tools
https://www.fda.gov/media/87134/download
CDRH








September 21, 2017 20 Software as a Medical Device (SaMD): Clinical Evaluation
http://www.imdrf.org/docs/imdrf/final/technical/imdrf‑tech‑170921‑samd‑n41‑clinical‑
evaluation_1.pdf
IMDRF, and SaMD 
WG
October 25, 2017 8 Deciding When to Submit a 510(k) for a Change to an Existing Device
https://www.fda.gov/media/99812/download
CDRH and OPEQ
October 25, 2017 21 Deciding When to Submit a 510(k) for a Software Change to an Existing Device
https://www.fda.gov/media/99785/download
CDRH and OPEQ
December 08, 2017 22 Software as a Medical Device (SAMD): Clinical Evaluation
https://www.fda.gov/media/100714/download
CDRH, OSPTI, and 
DDH




January 08, 2019 23 Developing a Software Precertification Program, A Working Model (v1.0 January 
2019)
https://www.fda.gov/media/119722/download
CDRH, OSPTI, and 
DDH
Contd...
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Supplemental Table 1: Contd...
Date n* Title Issuer
April 02, 2019 24a Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine 
Learning (AI/ML)‑Based Software as a Medical Device (SaMD) ‑ Discussion Paper 
and Request for Feedback
https://www.fda.gov/files/medical%20devices/published/US‑FDA‑Artificial‑
Intelligence‑and‑Machine‑Learning‑Discussion‑Paper.pdf
CDRH, OSPTI, and 
DDH




May 07, 2019 5 Requests for Feedback and Meetings for Medical Device Submission: The 
Q‑Submission Program
https://www.fda.gov/media/114034/download
CDRH, OPEQ, ORP, 
and DRP1
September 27, 2019 25 Off‑The‑Shelf Software Use in Medical Devices
https://www.fda.gov/media/71794/download
CDRH, OSPTI, and 
DDH
September 27, 2019 15 Clinical Decision Support Software
https://www.fda.gov/media/109618/download
CDRH, OSPTI, and 
DDH








January 28, 2020 24b Artificial Intelligence and Machine Learning in Software as a Medical Device ‑ update 
to: Proposed Regulatory Framework for Modifications to Artificial Intelligence/
Machine Learning (AI/ML)‑Based Software as a Medical Device (SaMD) ‑ Discussion 




April 24, 2020 28 Enforcement Policy for Remote Digital Pathology Devices During the Coronavirus 




No* refers to numbering in main Figure 1; a,bRefers to updated guidance documents. CBER: Center for Biologics Evaluation and Research; 
CDRH: Center for Devices and Radiological Health; CMS: Centers for Medicare and Medicaid Services; DDH: Division of Digital Health; DMGP: 
Division of Molecular Genetics and Pathology; DRP1: Division of Submission Support; FDA: Food and Drug Administration; IMDRF: International 
Medical Device Regulators Forum; OCD: Office of the Center Director; OHT7: Office of Health Technology 7; OPEQ: Office of Product Evaluation 
and Quality; ORP: Office of Regulatory Programs; OSEL: Office of Science and Engineering Laboratories; OSPTI: Office of Strategic Partnerships and 
Technology Innovation; SaMD WG: Software as a Medical Device Working Group
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Supplemental Table 2: The Alliance Steering Committee and Membership by Sector
Founders Affiliation Sector
Jochen K. Lennerz, MD, PhD Medical Director, Center for Integrated Diagnostics, Massachusetts General Hospital/Harvard 
Medical School
Academia
Esther Abels, MSc Vice President of Regulatory Affairs, Clinical Affairs and Strategic Business Development, 
PathAI
Industry
Brandon D. Gallas, PhD Mathematician, FDA/CDRH/OSEL/Division of Imaging, Diagnostics, and Software 
Reliability
Government
Steering Committee Affiliation Sector
Alain C. Borczuk, MD Professor of Pathology and Laboratory Medicine, Weill Cornell Medicine Academia
Amanda Lowe Managing Director of Americas, Visiopharm Corporation Industry
Ashish Sharma, PhD Associate Professor, Department of Biomedical Informatics, Emory University School of 
Medicine
Academia
Clive R. Taylor, MD, DPhil Professor Emeritus, University Southern California Academia
David A. Clunie, MBBS Owner, PixelMed Publishing, LLC Industry
Frank R. Dookie, MBA CEO and President, Sales Management Operations Consulting, Inc.; Strategic Consultant, 
JAV Advisors Corp.
Industry
Gina Giannini, MS Manager of Regulatory Affairs, Digital Pathology, Roche Tissue Diagnostics Industry
Hetal D. Marble, PhD Program Manage of Biomarker Development and CDx, Center for Integrated Diagnostics, 
Massachusetts General Hospital/Harvard Medical School
Academia
Jithesh Veetil, PhD Program Director of Data Science and Technology, Medical Device Innovation Consortium Nonprofit
Joachim H. Schmid, PhD Vice President of Research and Development, Digital Pathology, Roche Tissue Diagnostics Industry
Jon Hunt, PhD Vice President of Clinical Science and Technology, Medical Device Innovation Consortium Nonprofit
Keyvan Farahani, PhD Program Director, National Cancer Institute Government
Lakshman Ramamurthy, PhD Head of Regulatory Affairs, Precision Medicine and Digital Health, GlaxoSmithKline Inc. Industry
Laura Lasiter, PhD Director of Health Policy, Friends Of Cancer Research Nonprofit
Mark D. Zarella, PhD Deputy Director of Informatics, Department of Pathology, Johns Hopkins University Academia
Markus D. Herrmann, MD, PhD Director of Computational Pathology, Massachusetts General Hospital/Harvard Medical 
School
Academia
Matthew G. Hanna, MD Director of Digital Pathology Informatics, Assistant Attending Pathologist, Memorial Sloan 
Kettering Cancer Center
Academia
Matthew O. Leavitt, MD Chairman, Founder, and Chief Medical Officer, LUMEA Industry
Mike Bonham, MD, PhD Chief Medical Officer, Proscia Inc. Industry
Michael Isaacs Director of Clinical Informatics and Business Development, Washington University School of 
Medicine 
Academia
Pamela W. Goldberg, MBA President and Chief Executive Officer, Medical Device Innovation Consortium Nonprofit
Richard Huang, MD Clinical Informatics Fellow, Massachusetts General Hospital/Harvard Medical School Academia
S. Joseph Sirintrapun, MD Director of Pathology Informatics, Associate Attending Pathologist, Memorial Sloan 
Kettering Cancer Center
Academia
Sarah N. Dudgeon, MPH Research Fellow, FDA/CDRH/OSEL/Division of Imaging, Diagnostics, and Software 
Reliability
Government
Scott M. Blakely Business Development Manager of Whole Slide Imaging and Digital Pathology, Hamamatsu 
Corporation USA
Industry
Steven Barbee President, JAV Advisors Corp Industry
Overall Membership By Sector 
(Total: 320)
Academia: 102 Members Industry: 128 Members
Government: 76 Members Nonprofit: 14 Members
CDRH: Center for Devices and Radiological Health; OSEL: Office of Science and Engineering Laboratories; FDA: Food and Drug Administration
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Supplemental Table 3: Survey questions and answer 











2 How many papers have you 
published about digital pathology?
Open ended






4 Are you familiar with the MDIC? Yes
No
5 Should patient advocacy groups 
be a part of the Alliance?
Yes
No





7 Should the Alliance focus on 



























DICOM: Digital Imaging and Communications in Medicine (here 
referring to an interoperable file format for digital pathology); FDA: Food 
and Drug Administration; MDIC: Medical Device Innovation Consortium
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